NOV-110102

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameNOV-110102
Drug Alias NameNOV-1101 (National OncoVenture)DLK1-targeting mAb (National OncoVenture)NOV-110102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProtein delta homolog 1 inhibitors
TargetsProtein delta homolog 1
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Oncoventure
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Oncoventure
Active IndicationsN/A
Inactive IndicationsSolid tumoursPancreatic NeoplasmsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A